The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
Imo all safety studies should be duplicated, with one run by someone that wants the study to give a safe and effective conclusion and another run by someone who wants the study to give a dangerous or ineffective conclusion. Both studies monitored by neutral parties that are rewarded based on how long the studies stand up for. And no NDAs (or at least no NDAs that don’t expire once the product hits the market) so that all three can be vocal about any issues they had with how the others wanted things run.
Imo all safety studies should be duplicated, with one run by someone that wants the study to give a safe and effective conclusion and another run by someone who wants the study to give a dangerous or ineffective conclusion. Both studies monitored by neutral parties that are rewarded based on how long the studies stand up for. And no NDAs (or at least no NDAs that don’t expire once the product hits the market) so that all three can be vocal about any issues they had with how the others wanted things run.
And criminal charges for any kind of corruption.